Market Overview

Morgan Stanley: Quest Diagnostics Has Balanced Risk-Reward

Morgan Stanley: Quest Diagnostics Has Balanced Risk-Reward
Related DGX
56 Biggest Movers From Yesterday
44 Stocks Moving In Tuesday's Mid-Day Session

Quest Diagnostics Inc (NYSE: DGX) shares have derated over the last year, as the stock trades only slightly above its closest peer Laboratory Corp. of America Holdings (NYSE: LH), according to Morgan Stanley. 

The Analyst

Morgan Stanley analyst Ricky Goldwasser upgraded Quest Diagnostics from Underweight to Equal-weight and increased the price target from $95 to $103.

The Thesis

Quest Diagnostics' balanced growth strategy supports a mid-single-digit growth rate, with tuck-in acquisitions likely to supplement the company's growth profile, Goldwasser said in a Wednesday note. (See the analyst's track record here.) 

The diagnostic company's organic growth accelerated from an average of 0.8 percent between 2014-2016 to 1.9 percent in 2017, the analyst said. 

Medicare reimbursement cuts represent multiyear headwinds to earnings, Goldwasser said. The impact, which has already been quantified by Quest, is reflected in the share price, she said. Morgan Stanley estimates the reimbursement cut will represent a 90-to-150-basis point annual headwind to Quest's top line, which Goldwasser said will have a pass-through effect on gross profit margin in 2018-2020.

Quest must offset the rate cuts by delivering on annual cost cuts of $75 million to $85 million, the analyst said. 

Morgan Stanley revised its estimates for Quest Diagnostics to reflect the new accounting treatment of unpaid tests, guidance on the tax reform benefit and investments and greater volume contribution from acquisitions. While the firm lowered its revenue estimates for the period from 2018-2020, it raised its earnings per share estimates.

"We see upside optionality if UnitedHealth Group Inc (NYSE: UNH) adds Quest to its national lab network in 2019, reflected in our bull case." 

The Price Action

Quest Diagnostics shares are up about 6 percent over the past year.

Related Links:

3 Reasons Baird Downgraded Laboratory Corp Of America

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Latest Ratings for DGX

Oct 2018Credit SuisseMaintainsOutperformOutperform
Oct 2018BarclaysMaintainsOverweightOverweight
Oct 2018CitigroupMaintainsNeutralNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Rick GoldwasserAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (DGX + LH)

View Comments and Join the Discussion!

Latest Ratings

BKNGWells FargoUpgrades0.0
DARJP MorganUpgrades25.0
HPCredit SuisseUpgrades65.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Costco Falls Amid Allegations Of Kickbacks Related To Prescription Drugs

Adidas Continues North American Tear With 31% Sales Growth